{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:53:50Z","timestamp":1790873630555,"version":"4.1.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T00:00:00Z","timestamp":1658361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100009227","name":"Department of Medicine, University of Toronto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009227","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s40263-022-00937-x","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T14:12:38Z","timestamp":1658412758000},"page":"859-876","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Antiseizure Drugs and Movement Disorders"],"prefix":"10.1007","volume":"36","author":[{"given":"Michel","family":"S\u00e1enz-Farret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina A. J.","family":"Tijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Eliashiv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-0180","authenticated-orcid":false,"given":"Alfonso","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,21]]},"reference":[{"issue":"8","key":"937_CR1","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1136\/jnnp-2018-320039","volume":"90","author":"ME Freitas","year":"2019","unstructured":"Freitas ME, Ruiz-Lopez M, Dalmau J, Erro R, Privitera M, Andrade D, et al. Seizures and movement disorders: phenomenology, diagnostic challenges and therapeutic approaches. J Neurol Neurosurg Psychiatry. 2019;90(8):920\u20138.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"937_CR2","doi-asserted-by":"publisher","first-page":"4202","DOI":"10.3390\/ijms22084202","volume":"22","author":"C Spagnoli","year":"2021","unstructured":"Spagnoli C, Fusco C, Percesepe A, Leuzzi V, Pisani F. Genetic neonatal-onset epilepsies and developmental\/epileptic encephalopathies with movement disorders: a systematic review. Int J Mol Sci. 2021;22(8):4202.","journal-title":"Int J Mol Sci"},{"key":"937_CR3","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.parkreldis.2018.10.021","volume":"61","author":"A Fasano","year":"2019","unstructured":"Fasano A, Di Bonaventura C, Bove F, Espay AJ, Morgante F, Fabbrini G, et al. Movement disorders phenomenology in focal motor seizures. Parkinsonism Relat Disord. 2019;61:161\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"937_CR4","doi-asserted-by":"crossref","unstructured":"de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 1997;62(1):10\u20135.","DOI":"10.1136\/jnnp.62.1.10"},{"issue":"12","key":"937_CR5","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1002\/mds.23828","volume":"26","author":"E Bondon-Guitton","year":"2011","unstructured":"Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism: a review of 17 years\u2019 experience in a regional pharmacovigilance center in France. Mov Disord. 2011;26(12):2226\u201331.","journal-title":"Mov Disord"},{"key":"937_CR6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.seizure.2018.01.019","volume":"56","author":"PD Shanmugarajah","year":"2018","unstructured":"Shanmugarajah PD, Hoggard N, Aeschlimann DP, Aeschlimann PC, Dennis GJ, Howell SJ, et al. Phenytoin-related ataxia in patients with epilepsy: clinical and radiological characteristics. Seizure. 2018;56:26\u201330.","journal-title":"Seizure."},{"issue":"7","key":"937_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.seizure.2013.03.016","volume":"22","author":"G Zaccara","year":"2013","unstructured":"Zaccara G, Giovannelli F, Maratea D, Fadda V, Verrotti A. Neurological adverse events of new generation sodium blocker antiepileptic drugs: meta-analysis of randomized, double-blinded studies with eslicarbazepine acetate, lacosamide and oxcarbazepine. Seizure. 2013;22(7):528\u201336.","journal-title":"Seizure."},{"key":"937_CR8","doi-asserted-by":"crossref","unstructured":"Ferner RE, Day R, Bradberry SM. Phenytoin and damage to the cerebellum: a systematic review of published cases. Expert Opin Drug Saf. 2022.","DOI":"10.1080\/14740338.2022.2058487"},{"issue":"10","key":"937_CR9","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/S1474-4422(10)70193-9","volume":"9","author":"JM Dijk","year":"2010","unstructured":"Dijk JM, Tijssen MA. Management of patients with myoclonus: available therapies and the need for an evidence-based approach. Lancet Neurol. 2010;9(10):1028\u201336.","journal-title":"Lancet Neurol"},{"issue":"3","key":"937_CR10","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1212\/WNL.33.3.296","volume":"33","author":"A Baruzzi","year":"1983","unstructured":"Baruzzi A, Procaccianti G, Martinelli P, Riva R, Denoth F, Montanaro N, et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology. 1983;33(3):296\u2013300.","journal-title":"Neurology"},{"issue":"1","key":"937_CR11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/mds.870060112","volume":"6","author":"E Sasso","year":"1991","unstructured":"Sasso E, Perucca E, Fava R, Calzetti S. Quantitative comparison of barbiturates in essential hand and head tremor. Mov Disord. 1991;6(1):65\u20138.","journal-title":"Mov Disord"},{"issue":"5","key":"937_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1097\/00002826-199110000-00008","volume":"14","author":"F Cabrera-Valdivia","year":"1991","unstructured":"Cabrera-Valdivia F, Jimenez-Jimenez FJ, Garcia Albea E, Tejeiro-Martinez J, Vaquero Ruiperez JA, Ayuso-Peralta L. Orthostatic tremor: successful treatment with phenobarbital. Clin Neuropharmacol. 1991;14(5):438\u201341.","journal-title":"Clin Neuropharmacol"},{"key":"937_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.5334\/tohm.629","volume":"11","author":"TA Conte","year":"2021","unstructured":"Conte TA, Coutinho L, Teive HAG. Negative myoclonus secondary to thalamic infarction: case report. Tremor Other Hyperkinet Mov (N Y). 2021;11:25.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"issue":"2","key":"937_CR14","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1176\/ajp.138.2.189","volume":"138","author":"A Bobruff","year":"1981","unstructured":"Bobruff A, Gardos G, Tarsy D, Rapkin RM, Cole JO, Moore P. Clonazepam and phenobarbital in tardive dyskinesia. Am J Psychiatry. 1981;138(2):189\u201393.","journal-title":"Am J Psychiatry"},{"issue":"9","key":"937_CR15","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1136\/jnnp.48.9.911","volume":"48","author":"LJ Findley","year":"1985","unstructured":"Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985;48(9):911\u20135.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"937_CR16","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1002\/mds.870090418","volume":"9","author":"M Poersch","year":"1994","unstructured":"Poersch M. Orthostatic tremor: combined treatment with primidone and clonazepam. Mov Disord. 1994;9(4):467.","journal-title":"Mov Disord"},{"issue":"10","key":"937_CR17","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1111\/ene.14326","volume":"27","author":"F Scheibe","year":"2020","unstructured":"Scheibe F, Neumann WJ, Lange C, Scheel M, Furth C, Kohnlein M, et al. Movement disorders after hypoxic brain injury following cardiac arrest in adults. Eur J Neurol. 2020;27(10):1937\u201347.","journal-title":"Eur J Neurol"},{"issue":"4","key":"937_CR18","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1007\/s13311-020-00922-6","volume":"17","author":"AB Pena","year":"2020","unstructured":"Pena AB, Caviness JN. Physiology-based treatment of myoclonus. Neurotherapeutics. 2020;17(4):1665\u201380.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"937_CR19","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1212\/WNL.26.1.24","volume":"26","author":"MA Goldberb","year":"1976","unstructured":"Goldberb MA, Dorman JD. Intention myoclonus: successful treatment with clonazepam. Neurology. 1976;26(1):24\u20136.","journal-title":"Neurology"},{"issue":"5","key":"937_CR20","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00702-010-0366-y","volume":"117","author":"VK Paliwal","year":"2010","unstructured":"Paliwal VK, Chandra S, Verma R, Kalita J, Misra UK. Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis? J Neural Transm (Vienna). 2010;117(5):613\u20135.","journal-title":"J Neural Transm (Vienna)"},{"issue":"4","key":"937_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1001\/archneur.1983.04050040084019","volume":"40","author":"R Levy","year":"1983","unstructured":"Levy R, Plassche W, Riggs J, Shoulson I. Spinal myoclonus related to an arteriovenous malformation: response to clonazepam therapy. Arch Neurol. 1983;40(4):254\u20135.","journal-title":"Arch Neurol"},{"issue":"7","key":"937_CR22","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.parkreldis.2014.03.013","volume":"20","author":"TC Yaltho","year":"2014","unstructured":"Yaltho TC, Ondo WG. Orthostatic tremor: a review of 45 cases. Parkinsonism Relat Disord. 2014;20(7):723\u20135.","journal-title":"Parkinsonism Relat Disord"},{"key":"937_CR23","doi-asserted-by":"crossref","unstructured":"Hassan A, Caviness J. Slow orthostatic tremor: review of the current evidence. Tremor Other Hyperkinet Mov (N Y). 2019;9.","DOI":"10.5334\/tohm.513"},{"key":"937_CR24","doi-asserted-by":"publisher","first-page":"40","DOI":"10.5334\/tohm.188","volume":"10","author":"S Bhattacharjee","year":"2020","unstructured":"Bhattacharjee S. Palatal tremor: pathophysiology, clinical features, investigations, management and future challenges. Tremor Other Hyperkinet Mov (N Y). 2020;10:40.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"issue":"4","key":"937_CR25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000115809","volume":"24","author":"R Sandyk","year":"1985","unstructured":"Sandyk R. Successful treatment of neuroleptic-induced akathisia with baclofen and clonazepam: a case report. Eur Neurol. 1985;24(4):286\u20138.","journal-title":"Eur Neurol"},{"issue":"6","key":"937_CR26","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1176\/ajp.144.6.823-a","volume":"144","author":"SP Kutcher","year":"1987","unstructured":"Kutcher SP, Mackenzie S, Galarraga W, Szalai J. Clonazepam treatment of adolescents with neuroleptic-induced akathisia. Am J Psychiatry. 1987;144(6):823\u20134.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"937_CR27","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/j.1600-0447.1989.tb01308.x","volume":"80","author":"J Horiguchi","year":"1989","unstructured":"Horiguchi J, Nishimatsu O, Inami Y. Successful treatment with clonazepam for neuroleptic-induced akathisia. Acta Psychiatr Scand. 1989;80(1):106\u20137.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"937_CR28","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00002826-199406000-00003","volume":"17","author":"D Pujalte","year":"1994","unstructured":"Pujalte D, Bottai T, Hue B, Alric R, Pouget R, Blayac JP, et al. A double-blind comparison of clonazepam and placebo in the treatment of neuroleptic-induced akathisia. Clin Neuropharmacol. 1994;17(3):236\u201342.","journal-title":"Clin Neuropharmacol"},{"key":"937_CR29","doi-asserted-by":"crossref","unstructured":"Lima AR, Soares-Weiser K, Bacaltchuk J, Barnes TR. Benzodiazepines for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev. 2002;1:CD001950.","DOI":"10.1002\/14651858.CD003727.pub2"},{"issue":"3","key":"937_CR30","first-page":"72","volume":"51","author":"SM Thippaiah","year":"2021","unstructured":"Thippaiah SM, Fargason RE, Birur B. Struggling to find effective pharmacologic options for akathisia? B-CALM! Psychopharmacol Bull. 2021;51(3):72\u20138.","journal-title":"Psychopharmacol Bull"},{"issue":"4","key":"937_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1176\/ajp.147.4.445","volume":"147","author":"GK Thaker","year":"1990","unstructured":"Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445\u201351.","journal-title":"Am J Psychiatry"},{"key":"937_CR32","doi-asserted-by":"crossref","unstructured":"Bergman H, Bhoopathi PS, Soares-Weiser K. Benzodiazepines for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018;1:CD000205.","DOI":"10.1002\/14651858.CD000205.pub3"},{"issue":"8","key":"937_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.5694\/j.1326-5377.1976.tb140550.x","volume":"1","author":"JB Peiris","year":"1976","unstructured":"Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust. 1976;1(8):225\u20137.","journal-title":"Med J Aust"},{"issue":"1","key":"937_CR34","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/mds.870050107","volume":"5","author":"UJ Povlsen","year":"1990","unstructured":"Povlsen UJ, Pakkenberg H. Effect of intravenous injection of biperiden and clonazepam in dystonia. Mov Disord. 1990;5(1):27\u201331.","journal-title":"Mov Disord"},{"issue":"4","key":"937_CR35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1159\/000085917","volume":"51","author":"A Saletu","year":"2005","unstructured":"Saletu A, Parapatics S, Saletu B, Anderer P, Prause W, Putz H, et al. On the pharmacotherapy of sleep bruxism: placebo-controlled polysomnographic and psychometric studies with clonazepam. Neuropsychobiology. 2005;51(4):214\u201325.","journal-title":"Neuropsychobiology"},{"key":"937_CR36","doi-asserted-by":"crossref","unstructured":"Roshi, Tandon VR, Mahajan A, Sharma S, Khajuria V. Comparative efficacy and safety of clonazepam versus nortriptyline in restless leg syndrome among forty plus women: a prospective, open-label randomized study. J Midl Health. 2019;10(4):197\u2013203.","DOI":"10.4103\/jmh.JMH_26_18"},{"key":"937_CR37","doi-asserted-by":"crossref","unstructured":"Murata M, Hasegawa K, Kanazawa I; Japan Zonisamide on PD Study Group. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology. 2007;68(1):45\u201350.","DOI":"10.1212\/01.wnl.0000250236.75053.16"},{"issue":"10","key":"937_CR38","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1002\/mds.26286","volume":"30","author":"M Murata","year":"2015","unstructured":"Murata M, Hasegawa K, Kanazawa I, Fukasaka J, Kochi K, Shimazu R, et al. Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study. Mov Disord. 2015;30(10):1343\u201350.","journal-title":"Mov Disord"},{"key":"937_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120026","volume":"430","author":"Y Tsuboi","year":"2021","unstructured":"Tsuboi Y, Nakamura M, Maruyama H, Matsumoto Y. Zonisamide improves wearing off in Parkinson\u2019s disease without exacerbating dyskinesia: post hoc analysis of phase 2 and phase 3 clinical trials. J Neurol Sci. 2021;430: 120026.","journal-title":"J Neurol Sci"},{"issue":"8","key":"937_CR40","doi-asserted-by":"publisher","first-page":"e664","DOI":"10.1212\/WNL.0000000000005010","volume":"90","author":"M Murata","year":"2018","unstructured":"Murata M, Odawara T, Hasegawa K, Iiyama S, Nakamura M, Tagawa M, et al. Adjunct zonisamide to levodopa for DLB parkinsonism: a randomized double-blind phase 2 study. Neurology. 2018;90(8):e664\u201372.","journal-title":"Neurology"},{"issue":"18","key":"937_CR41","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1212\/WNL.0000000000002631","volume":"86","author":"E Hainque","year":"2016","unstructured":"Hainque E, Vidailhet M, Cozic N, Charbonnier-Beaupel F, Thobois S, Tranchant C, et al. A randomized, controlled, double-blind, crossover trial of zonisamide in myoclonus-dystonia. Neurology. 2016;86(18):1729\u201335.","journal-title":"Neurology"},{"issue":"3","key":"937_CR42","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.pediatrneurol.2010.04.008","volume":"43","author":"RT Egel","year":"2010","unstructured":"Egel RT, Hoganson GE, Katerji MA, Borenstein MJ. Zonisamide ameliorates symptoms of secondary paroxysmal dystonia. Pediatr Neurol. 2010;43(3):205\u20138.","journal-title":"Pediatr Neurol"},{"key":"937_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.pediatrneurol.2020.06.017","volume":"111","author":"R Matsuura","year":"2020","unstructured":"Matsuura R, Hamano SI, Hiwatari E, Ikemoto S, Hirata Y, Koichihara R, et al. Zonisamide therapy for patients with paroxysmal kinesigenic dyskinesia. Pediatr Neurol. 2020;111:23\u20136.","journal-title":"Pediatr Neurol"},{"issue":"10","key":"937_CR44","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1212\/WNL.59.10.1573","volume":"59","author":"D Garcia-Borreguero","year":"2002","unstructured":"Garcia-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G. Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study. Neurology. 2002;59(10):1573\u20139.","journal-title":"Neurology"},{"key":"937_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.751643","volume":"15","author":"X Zhou","year":"2021","unstructured":"Zhou X, Du J, Liang Y, Dai C, Zhao L, Liu X, et al. The efficacy and safety of pharmacological treatments for restless legs syndrome: systemic review and network meta-analysis. Front Neurosci. 2021;15: 751643.","journal-title":"Front Neurosci"},{"issue":"4","key":"937_CR46","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/1531-8257(200007)15:4<678::AID-MDS1012>3.0.CO;2-0","volume":"15","author":"W Ondo","year":"2000","unstructured":"Ondo W, Hunter C, Vuong KD, Schwartz K, Jankovic J. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15(4):678\u201382.","journal-title":"Mov Disord"},{"issue":"3","key":"937_CR47","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1212\/WNL.51.3.880","volume":"51","author":"M Onofrj","year":"1998","unstructured":"Onofrj M, Thomas A, Paci C, D\u2019Andreamatteo G. Gabapentin in orthostatic tremor: results of a double-blind crossover with placebo in four patients. Neurology. 1998;51(3):880\u20132.","journal-title":"Neurology"},{"issue":"2","key":"937_CR48","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/WNF.0b013e3180d09969","volume":"31","author":"GS Connor","year":"2008","unstructured":"Connor GS, Edwards K, Tarsy D. Topiramate in essential tremor: findings from double-blind, placebo-controlled, crossover trials. Clin Neuropharmacol. 2008;31(2):97\u2013103.","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"937_CR49","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/mds.22068","volume":"23","author":"C Kobylecki","year":"2008","unstructured":"Kobylecki C, Marshall AG, Varma A, Kellett MW, Dick JP, Silverdale MA. Topiramate-responsive cerebellar axial postural tremor. Mov Disord. 2008;23(8):1189\u201391.","journal-title":"Mov Disord"},{"issue":"7","key":"937_CR50","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/mds.20086","volume":"19","author":"EM Gatto","year":"2004","unstructured":"Gatto EM, Uribe Roca C, Raina G, Gorja M, Folgar S, Micheli FE. Vascular hemichorea\/hemiballism and topiramate. Mov Disord. 2004;19(7):836\u20138.","journal-title":"Mov Disord"},{"issue":"1","key":"937_CR51","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/mds.20283","volume":"20","author":"YG Huang","year":"2005","unstructured":"Huang YG, Chen YC, Du F, Li R, Xu GL, Jiang W, et al. Topiramate therapy for paroxysmal kinesigenic choreoathetosis. Mov Disord. 2005;20(1):75\u20137.","journal-title":"Mov Disord"},{"issue":"1","key":"937_CR52","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1136\/jnnp.2009.185348","volume":"81","author":"J Jankovic","year":"2010","unstructured":"Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010;81(1):70\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"19","key":"937_CR53","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1212\/WNL.0000000000007467","volume":"92","author":"T Pringsheim","year":"2019","unstructured":"Pringsheim T, Holler-Managan Y, Okun MS, Jankovic J, Piacentini J, Cavanna AE, et al. Comprehensive systematic review summary: treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology. 2019;92(19):907\u201315.","journal-title":"Neurology"},{"issue":"12","key":"937_CR54","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3109\/00207454.2012.715109","volume":"122","author":"Y Yang","year":"2012","unstructured":"Yang Y, Su Y, Guo Y, Ding Y, Xu S, Jiang Y, et al. Oxcarbazepine versus carbamazepine in the treatment of paroxysmal kinesigenic dyskinesia. Int J Neurosci. 2012;122(12):719\u201322.","journal-title":"Int J Neurosci"},{"issue":"4","key":"937_CR55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/WNF.0000000000000149","volume":"39","author":"A Kumar","year":"2016","unstructured":"Kumar A, Szekely A, Jabbari B. Effective treatment of paroxysmal nonkinesigenic dyskinesia with oxcarbazepine. Clin Neuropharmacol. 2016;39(4):201\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"937_CR56","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/WNF.0b013e31818f1125","volume":"32","author":"L Jimenez-Trevino","year":"2009","unstructured":"Jimenez-Trevino L. Oxcarbazepine treatment of restless legs syndrome: three case reports. Clin Neuropharmacol. 2009;32(3):169\u201370.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"937_CR57","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1212\/WNL.56.3.411","volume":"56","author":"GL Krauss","year":"2001","unstructured":"Krauss GL, Bergin A, Kramer RE, Cho YW, Reich SG. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology. 2001;56(3):411\u20132.","journal-title":"Neurology"},{"issue":"6","key":"937_CR58","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1212\/WNL.57.6.1112","volume":"57","author":"SJ Frucht","year":"2001","unstructured":"Frucht SJ, Louis ED, Chuang C, Fahn S. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology. 2001;57(6):1112\u20134.","journal-title":"Neurology"},{"issue":"4","key":"937_CR59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.4088\/JCP.v69n0405","volume":"69","author":"SW Woods","year":"2008","unstructured":"Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546\u201354.","journal-title":"J Clin Psychiatry"},{"issue":"8","key":"937_CR60","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/mds.20835","volume":"21","author":"S Konitsiotis","year":"2006","unstructured":"Konitsiotis S, Pappa S, Mantas C, Mavreas V. Levetiracetam in tardive dyskinesia: an open label study. Mov Disord. 2006;21(8):1219\u201321.","journal-title":"Mov Disord"},{"issue":"23","key":"937_CR61","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1212\/WNL.0b013e3181e1ce73","volume":"74","author":"D Garcia-Borreguero","year":"2010","unstructured":"Garcia-Borreguero D, Larrosa O, Williams AM, Albares J, Pascual M, Palacios JC, et al. Treatment of restless legs syndrome with pregabalin: a double-blind, placebo-controlled study. Neurology. 2010;74(23):1897\u2013904.","journal-title":"Neurology"},{"issue":"11","key":"937_CR62","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1002\/mds.21629","volume":"22","author":"TA Zesiewicz","year":"2007","unstructured":"Zesiewicz TA, Ward CL, Hauser RA, Salemi JL, Siraj S, Wilson MC, et al. A pilot, double-blind, placebo-controlled trial of pregabalin (Lyrica) in the treatment of essential tremor. Mov Disord. 2007;22(11):1660\u20133.","journal-title":"Mov Disord"},{"issue":"1\u20132","key":"937_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.jns.2009.06.044","volume":"285","author":"JM Ferrara","year":"2009","unstructured":"Ferrara JM, Kenney C, Davidson AL, Shinawi L, Kissel AM, Jankovic J. Efficacy and tolerability of pregabalin in essential tremor: a randomized, double-blind, placebo-controlled, crossover trial. J Neurol Sci. 2009;285(1\u20132):195\u20137.","journal-title":"J Neurol Sci"},{"issue":"6","key":"937_CR64","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1002\/mds.24928","volume":"27","author":"T Mathew","year":"2012","unstructured":"Mathew T, Aroor S, Nadig R, Sarma GR. Lacosamide in paroxysmal kinesigenic dyskinesia. Mov Disord. 2012;27(6):801\u20132.","journal-title":"Mov Disord"},{"issue":"8","key":"937_CR65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.braindev.2020.04.009","volume":"42","author":"G Furukawa","year":"2020","unstructured":"Furukawa G, Negishi Y, Takeuchi T, Ishihara N, Okumura A. Lacosamide for children with paroxysmal kinesigenic dyskinesia. Brain Dev. 2020;42(8):617\u201320.","journal-title":"Brain Dev"},{"key":"937_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.826897","volume":"13","author":"JH Geng","year":"2022","unstructured":"Geng JH, Zheng Y, Li QF, Hou Q, Wang XH, Jiang Y. Case report: a case of concomitant paroxysmal kinesigenic dyskinesia and epilepsy: can we treat two birds with one stone? Front Neurol. 2022;13: 826897.","journal-title":"Front Neurol"},{"issue":"4","key":"937_CR67","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/WNF.0b013e3181e1613f","volume":"33","author":"N Galldiks","year":"2010","unstructured":"Galldiks N, Timmermann L, Fink GR, Burghaus L. Posthypoxic myoclonus (Lance-Adams syndrome) treated with lacosamide. Clin Neuropharmacol. 2010;33(4):216\u20137.","journal-title":"Clin Neuropharmacol"},{"key":"937_CR68","doi-asserted-by":"crossref","unstructured":"Salari M, Asadi S, Etemadifar M, Rezaee M. Myoclonic dystonia (DYT11) responsive to lacosamide: a case report. Acta Neurol Belg. 2021.","DOI":"10.1007\/s13760-021-01756-5"},{"key":"937_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.5334\/tohm.414","volume":"8","author":"M Ruiz-Julian","year":"2018","unstructured":"Ruiz-Julian M, Orozco JL, Gironell A. Complete resolution of symptoms of primary orthostatic tremor with perampanel. Tremor Other Hyperkinet Mov (N Y). 2018;8:552.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"key":"937_CR70","doi-asserted-by":"crossref","unstructured":"Wadhwa A, Schaefer SM. Successful treatment of primary orthostatic tremor using perampanel. Tremor Other Hyperkinet Mov (N Y). 2019;9.","DOI":"10.5334\/tohm.481"},{"key":"937_CR71","doi-asserted-by":"crossref","unstructured":"Gironell A, Marin-Lahoz J. Primary orthostatic tremor: experience of perampanel use in 20 patients. Tremor Other Hyperkinet Mov (N Y). 2019;9.","DOI":"10.5334\/tohm.470"},{"issue":"4","key":"937_CR72","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/mdc3.12927","volume":"7","author":"A Handforth","year":"2020","unstructured":"Handforth A, Tse W, Elble RJ. A pilot double-blind randomized trial of perampanel for essential tremor. Mov Disord Clin Pract. 2020;7(4):399\u2013404.","journal-title":"Mov Disord Clin Pract."},{"key":"937_CR73","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.parkreldis.2018.10.010","volume":"60","author":"A Gironell","year":"2019","unstructured":"Gironell A, Pascual-Sedano B, Marin-Lahoz J. Perampanel, a new hope for essential tremor: an open label trial. Parkinsonism Relat Disord. 2019;60:171\u20132.","journal-title":"Parkinsonism Relat Disord"},{"key":"937_CR74","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.sleep.2017.03.012","volume":"34","author":"D Garcia-Borreguero","year":"2017","unstructured":"Garcia-Borreguero D, Cano I, Granizo JJ. Treatment of restless legs syndrome with the selective AMPA receptor antagonist perampanel. Sleep Med. 2017;34:105\u20138.","journal-title":"Sleep Med"},{"key":"937_CR75","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ebcr.2016.05.001","volume":"6","author":"BJ Steinhoff","year":"2016","unstructured":"Steinhoff BJ, Bacher M, Kurth C, Staack AM, Kornmeier R. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep. 2016;6:28\u20139.","journal-title":"Epilepsy Behav Case Rep."},{"issue":"3","key":"937_CR76","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s13760-019-01259-4","volume":"120","author":"WA Kamel","year":"2020","unstructured":"Kamel WA, Al-Hashel JY, Abdulsalam AJ, Arabi M. Perampanel in refractory post-hypoxic myoclonus: see the difference! Acta Neurol Belg. 2020;120(3):741\u20132.","journal-title":"Acta Neurol Belg"},{"issue":"6","key":"937_CR77","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1097\/00002826-199619060-00009","volume":"19","author":"J Duarte","year":"1996","unstructured":"Duarte J, Sempere AP, Cabezas MC, Marcos J, Claveria LE. Postural myoclonus induced by phenytoin. Clin Neuropharmacol. 1996;19(6):536\u20138.","journal-title":"Clin Neuropharmacol"},{"issue":"9","key":"937_CR78","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/026990500421949","volume":"14","author":"WM Chi","year":"2000","unstructured":"Chi WM, Chua KS, Kong KH. Phenytoin-induced asterixis: uncommon or under-diagnozed? Brain Inj. 2000;14(9):847\u201350.","journal-title":"Brain Inj"},{"issue":"5","key":"937_CR79","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1212\/WNL.26.5.494","volume":"26","author":"EG Chalhub","year":"1976","unstructured":"Chalhub EG, Devivo DC, Volpe JJ. Phenytoin-induced dystonia and choreoathetosis in two retarded epileptic children. Neurology. 1976;26(5):494\u20138.","journal-title":"Neurology"},{"issue":"1","key":"937_CR80","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2174\/1574886313666181031161215","volume":"14","author":"DM Patel","year":"2019","unstructured":"Patel DM, Gurumukhani JK, Patel MV, Patel GR. Phenytoin induced chorea: a rare adverse effect of the drug. Curr Drug Saf. 2019;14(1):51\u20132.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"937_CR81","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mds.870110128","volume":"11","author":"LM Shulman","year":"1996","unstructured":"Shulman LM, Singer C, Weiner WJ. Phenytoin-induced focal chorea. Mov Disord. 1996;11(1):111\u20134.","journal-title":"Mov Disord"},{"issue":"19","key":"937_CR82","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182735eac","volume":"79","author":"BP Lucey","year":"2012","unstructured":"Lucey BP. Teaching video neuroImages: phenytoin-induced orofacial dyskinesias. Neurology. 2012;79(19): e177.","journal-title":"Neurology"},{"issue":"19","key":"937_CR83","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJM197805112981923","volume":"298","author":"PA Nausieda","year":"1978","unstructured":"Nausieda PA, Koller WC, Klawans HL, Weiner WJ. Phenytoin and choreic movements. N Engl J Med. 1978;298(19):1093\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"937_CR84","doi-asserted-by":"publisher","first-page":"111","DOI":"10.24953\/turkjped.2018.01.019","volume":"60","author":"T Acar","year":"2018","unstructured":"Acar T, Alkan G, Caksen H, Ertekin B, Ergin M, Kocak S, et al. Phenytoin induced dystonia. Turk J Pediatr. 2018;60(1):111\u20132.","journal-title":"Turk J Pediatr"},{"issue":"4","key":"937_CR85","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/00002826-198512000-00012","volume":"8","author":"M Goni","year":"1985","unstructured":"Goni M, Jimenez M, Feijoo M. Parkinsonism induced by phenytoin. Clin Neuropharmacol. 1985;8(4):383\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"11","key":"937_CR86","first-page":"981","volume":"47","author":"S Ertan","year":"2006","unstructured":"Ertan S, Ulu MO, Hanimoglu H, Tanriverdi T, Kafadar AM, Acar ZU, et al. Phenytoin-induced parkinsonism. Singapore Med J. 2006;47(11):981\u20133.","journal-title":"Singapore Med J"},{"issue":"1","key":"937_CR87","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1001\/archneur.1975.00490430066011","volume":"32","author":"JS Mendez","year":"1975","unstructured":"Mendez JS, Cotzias GC, Mena I, Papavasiliou PS. Diphenylhydantoin: blocking of levodopa effects. Arch Neurol. 1975;32(1):44\u20136.","journal-title":"Arch Neurol"},{"issue":"2","key":"937_CR88","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1001\/archneur.1975.00490440087017","volume":"32","author":"GJ Kirschberg","year":"1975","unstructured":"Kirschberg GJ. Dyskinesia: an unusual reaction to ethosuximide. Arch Neurol. 1975;32(2):137\u20138.","journal-title":"Arch Neurol"},{"issue":"5","key":"937_CR89","first-page":"527","volume":"132","author":"A Ehyai","year":"1978","unstructured":"Ehyai A, Kilroy AW, Fenichel GM. Dyskinesia and akathisia induced by ethosuximide. Am J Dis Child. 1978;132(5):527\u20138.","journal-title":"Am J Dis Child"},{"issue":"2","key":"937_CR90","first-page":"508","volume":"25","author":"BW Abou-Khalil","year":"2019","unstructured":"Abou-Khalil BW. Update on antiepileptic drugs 2019. Continuum (Minneap Minn). 2019;25(2):508\u201336.","journal-title":"Continuum (Minneap Minn)."},{"issue":"3","key":"937_CR91","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/00002826-199506000-00010","volume":"18","author":"MY Neufeld","year":"1995","unstructured":"Neufeld MY, Vishnevska S. Vigabatrin and multifocal myoclonus in adults with partial seizures. Clin Neuropharmacol. 1995;18(3):280\u20133.","journal-title":"Clin Neuropharmacol"},{"key":"937_CR92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jns.2016.12.022","volume":"373","author":"M Tombini","year":"2017","unstructured":"Tombini M, Pellegrino G, Assenza G, Di Lazzaro V. De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case. J Neurol Sci. 2017;373:31\u20132.","journal-title":"J Neurol Sci"},{"issue":"2","key":"937_CR93","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/JCP.0b013e318167465f","volume":"28","author":"P Fernandez Corcuera","year":"2008","unstructured":"Fernandez Corcuera P, Pomarol E, Amann B, McKenna P. Myoclonus provoked by lamotrigine in a bipolar patient. J Clin Psychopharmacol. 2008;28(2):248\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"47","key":"937_CR94","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008711","volume":"96","author":"ZF He","year":"2017","unstructured":"He ZF, Chen J, Zhou CN, Rao Z, Wang XH. Disabling tremor induced by long-term use of sodium valproate and lamotrigine: case report. Medicine (Baltimore). 2017;96(47): e8711.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"937_CR95","doi-asserted-by":"publisher","first-page":"18","DOI":"10.14802\/jmd.10005","volume":"3","author":"JH Yang","year":"2010","unstructured":"Yang JH, Chung SW, Kim JS. Action tremor associated with lamotrigine monotherapy. J Mov Disord. 2010;3(1):18\u20139.","journal-title":"J Mov Disord."},{"issue":"8","key":"937_CR96","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1053\/seiz.2001.0555","volume":"10","author":"M Zaatreh","year":"2001","unstructured":"Zaatreh M, Tennison M, D\u2019Cruz O, Beach RL. Anticonvulsants-induced chorea: a role for pharmacodynamic drug interaction? Seizure. 2001;10(8):596\u20139.","journal-title":"Seizure."},{"issue":"7","key":"937_CR97","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1177\/08830738030180070301","volume":"18","author":"KB Das","year":"2003","unstructured":"Das KB, Harris C, Smyth DP, Cross JH. Unusual side effects of lamotrigine therapy. J Child Neurol. 2003;18(7):479\u201380.","journal-title":"J Child Neurol"},{"issue":"2","key":"937_CR98","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0883073807308693","volume":"23","author":"MA Miller","year":"2008","unstructured":"Miller MA, Levsky ME. Choreiform dyskinesia following isolated lamotrigine overdose. J Child Neurol. 2008;23(2):243.","journal-title":"J Child Neurol"},{"issue":"12","key":"937_CR99","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1002\/mds.21125","volume":"21","author":"P Santens","year":"2006","unstructured":"Santens P, Claeys I, Vonck K, Boon P. Parkinsonism due to lamotrigine. Mov Disord. 2006;21(12):2269\u201370.","journal-title":"Mov Disord"},{"issue":"5","key":"937_CR100","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2010.02981.x","volume":"17","author":"M Sabolek","year":"2010","unstructured":"Sabolek M, Runge U. Lamotrigine induced dyskinesia in Parkinson\u2019s disease. Eur J Neurol. 2010;17(5): e37.","journal-title":"Eur J Neurol"},{"issue":"5","key":"937_CR101","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1212\/WNL.48.5.1282","volume":"48","author":"H Shinotoh","year":"1997","unstructured":"Shinotoh H, Vingerhoets FJ, Lee CS, Uitti RJ, Schulzer M, Calne DB, et al. Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. Neurology. 1997;48(5):1282\u20135.","journal-title":"Neurology"},{"issue":"10","key":"937_CR102","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1002\/mds.23120","volume":"25","author":"ES Musiek","year":"2010","unstructured":"Musiek ES, Anderson CT, Dahodwala NA, Pollard JR. Facial tic associated with lamotrigine in adults. Mov Disord. 2010;25(10):1512\u20133.","journal-title":"Mov Disord"},{"issue":"6","key":"937_CR103","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.4103\/0028-3886.333440","volume":"69","author":"JP Rissardo","year":"2021","unstructured":"Rissardo JP, Fornari Caprara AL. Lamotrigine-associated movement disorder: a literature review. Neurol India. 2021;69(6):1524\u201338.","journal-title":"Neurol India"},{"key":"937_CR104","doi-asserted-by":"crossref","unstructured":"Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: report of five pediatric cases. Epilepsia. 2000;41(7):862\u20137.","DOI":"10.1111\/j.1528-1157.2000.tb00254.x"},{"issue":"6","key":"937_CR105","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1016\/j.pnpbp.2007.04.015","volume":"31","author":"T Alkin","year":"2007","unstructured":"Alkin T, Onur E, Ozerdem A. Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1339\u201340.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"937_CR106","doi-asserted-by":"publisher","first-page":"e4","DOI":"10.1111\/j.1528-1167.2010.02967.x","volume":"52","author":"A Veerapandiyan","year":"2011","unstructured":"Veerapandiyan A, Gallentine WB, Winchester SA, Baker J, Kansagra SM, Mikati MA. Oculogyric crises secondary to lamotrigine overdosage. Epilepsia. 2011;52(3):e4-6.","journal-title":"Epilepsia"},{"issue":"1","key":"937_CR107","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1212\/WNL.45.1.185","volume":"45","author":"JM Kerrick","year":"1995","unstructured":"Kerrick JM, Kelley BJ, Maister BH, Graves NM, Leppik IE. Involuntary movement disorders associated with felbamate. Neurology. 1995;45(1):185\u20137.","journal-title":"Neurology"},{"issue":"13","key":"937_CR108","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1002\/mds.22094","volume":"23","author":"A Gironell","year":"2008","unstructured":"Gironell A, Martinez-Corral M, Pagonabarraga X, Kulisevsky J. Tiagabine for essential tremor: an open-label trial. Mov Disord. 2008;23(13):1955\u20136.","journal-title":"Mov Disord"},{"issue":"14","key":"937_CR109","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1002\/mds.21559","volume":"22","author":"TA Zesiewicz","year":"2007","unstructured":"Zesiewicz TA, Sullivan KL, Ward CL, Hauser RA. Tiagabine and exacerbation of essential tremor. Mov Disord. 2007;22(14):2132\u20133.","journal-title":"Mov Disord"},{"issue":"Suppl. 6","key":"937_CR110","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/j.1528-1157.1995.tb06009.x","volume":"36","author":"IE Leppik","year":"1995","unstructured":"Leppik IE. Tiagabine: the safety landscape. Epilepsia. 1995;36(Suppl. 6):S10\u20133.","journal-title":"Epilepsia"},{"issue":"7","key":"937_CR111","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1046\/j.1528-1157.2001.042007944.x","volume":"42","author":"T Wolanczyk","year":"2001","unstructured":"Wolanczyk T, Grabowska-Grzyb A. Transient dystonias in three patients treated with tiagabine. Epilepsia. 2001;42(7):944\u20136.","journal-title":"Epilepsia"},{"issue":"4","key":"937_CR112","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/j.1528-1167.2006.00530.x","volume":"47","author":"M Tombini","year":"2006","unstructured":"Tombini M, Pacifici L, Passarelli F, Rossini PM. Transient athetosis induced by tiagabine. Epilepsia. 2006;47(4):799\u2013800.","journal-title":"Epilepsia"},{"issue":"22","key":"937_CR113","doi-asserted-by":"publisher","first-page":"e2311","DOI":"10.1212\/WNL.0000000000009530","volume":"94","author":"SS Chung","year":"2020","unstructured":"Chung SS, French JA, Kowalski J, Krauss GL, Lee SK, Maciejowski M, et al. Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology. 2020;94(22):e2311\u201322.","journal-title":"Neurology"},{"issue":"6","key":"937_CR114","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/epi.16525","volume":"61","author":"MR Sperling","year":"2020","unstructured":"Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099\u2013108.","journal-title":"Epilepsia"},{"issue":"3","key":"937_CR115","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/WNF.0000000000000387","volume":"43","author":"JP Rissardo","year":"2020","unstructured":"Rissardo JP, Caprara ALF. Carbamazepine-, oxcarbazepine-, eslicarbazepine-associated movement disorder: a literature review. Clin Neuropharmacol. 2020;43(3):66\u201380.","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"937_CR116","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/j.1528-1157.1991.tb05255.x","volume":"32","author":"A Dhuna","year":"1991","unstructured":"Dhuna A, Pascual-Leone A, Talwar D. Exacerbation of partial seizures and onset of nonepileptic myoclonus with carbamazepine. Epilepsia. 1991;32(2):275\u20138.","journal-title":"Epilepsia"},{"issue":"2","key":"937_CR117","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1684\/epd.2012.0504","volume":"14","author":"A Magaudda","year":"2012","unstructured":"Magaudda A, Di Rosa G. Carbamazepine-induced non-epileptic myoclonus and tic-like movements. Epileptic Disord. 2012;14(2):172\u20133.","journal-title":"Epileptic Disord"},{"issue":"4","key":"937_CR118","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/00002826-198908000-00007","volume":"12","author":"R Kurlan","year":"1989","unstructured":"Kurlan R, Kersun J, Behr J, Leibovici A, Tariot P, Lichter D, et al. Carbamazepine-induced tics. Clin Neuropharmacol. 1989;12(4):298\u2013302.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"937_CR119","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1111\/j.1528-1157.1993.tb02119.x","volume":"34","author":"PL Robertson","year":"1993","unstructured":"Robertson PL, Garofalo EA, Silverstein FS, Komarynski MA. Carbamazepine-induced tics. Epilepsia. 1993;34(5):965\u20138.","journal-title":"Epilepsia"},{"issue":"2","key":"937_CR120","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/S0163-8343(01)00177-3","volume":"24","author":"R Stryjer","year":"2002","unstructured":"Stryjer R, Strous RD, Bar F, Ulman AM, Rabey JM. Segmental dystonia as the sole manifestation of carbamazepine toxicity. Gen Hosp Psychiatry. 2002;24(2):114\u20135.","journal-title":"Gen Hosp Psychiatry"},{"issue":"3","key":"937_CR121","doi-asserted-by":"publisher","first-page":"329","DOI":"10.4103\/0253-7613.182879","volume":"48","author":"S Bansal","year":"2016","unstructured":"Bansal S, Gill M, Bhasin C. Carbamazepine-induced dystonia in an adolescent. Indian J Pharmacol. 2016;48(3):329\u201330.","journal-title":"Indian J Pharmacol."},{"issue":"2","key":"937_CR122","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1097\/00004714-199404000-00012","volume":"14","author":"A Lazarus","year":"1994","unstructured":"Lazarus A. Tardive dyskinesia-like syndrome associated with lithium and carbamazepine. J Clin Psychopharmacol. 1994;14(2):146\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"937_CR123","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/jnnp.45.6.560","volume":"45","author":"K Bimpong-Buta","year":"1982","unstructured":"Bimpong-Buta K, Froescher W. Carbamazepine-induced choreoathetoid dyskinesias. J Neurol Neurosurg Psychiatry. 1982;45(6):560.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"937_CR124","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/WNF.0000000000000164","volume":"39","author":"V Montilla-Uzcategui","year":"2016","unstructured":"Montilla-Uzcategui V, Araujo-Unda H, Daza-Restrepo A, Saenz-Farret M, Micheli F. Paroxysmal nonkinesigenic dyskinesias responsive to carbamazepine in Fahr syndrome: a case report. Clin Neuropharmacol. 2016;39(5):262\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"3","key":"937_CR125","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/BF01037942","volume":"25","author":"O Lundvall","year":"1983","unstructured":"Lundvall O, Abom PE, Holm R. Carbamazepine in restless legs: a controlled pilot study. Eur J Clin Pharmacol. 1983;25(3):323\u20134.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"937_CR126","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0387-7604(01)00404-1","volume":"24","author":"F Genel","year":"2002","unstructured":"Genel F, Arslanoglu S, Uran N, Saylan B. Sydenham\u2019s chorea: clinical findings and comparison of the efficacies of sodium valproate and carbamazepine regimens. Brain Dev. 2002;24(2):73\u20136.","journal-title":"Brain Dev"},{"issue":"6","key":"937_CR127","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40263-016-0341-8","volume":"30","author":"F Brugger","year":"2016","unstructured":"Brugger F, Bhatia KP, Besag FM. Valproate-associated parkinsonism: a critical review of the literature. CNS Drugs. 2016;30(6):527\u201340.","journal-title":"CNS Drugs"},{"issue":"5","key":"937_CR128","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1097\/00002826-199310000-00009","volume":"16","author":"MJ Alvarez-Gomez","year":"1993","unstructured":"Alvarez-Gomez MJ, Vaamonde J, Narbona J, Barao M, Barona P, Brannan T, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol. 1993;16(5):451\u20135.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"937_CR129","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1111\/j.1528-1167.2006.00711.x","volume":"47","author":"AJ Ristic","year":"2006","unstructured":"Ristic AJ, Vojvodic N, Jankovic S, Sindelic A, Sokic D. The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy. Epilepsia. 2006;47(12):2183\u20135.","journal-title":"Epilepsia"},{"issue":"1","key":"937_CR130","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-2006-931471","volume":"39","author":"K Masmoudi","year":"2006","unstructured":"Masmoudi K, Gras-Champel V, Masson H, Andrejak M. Parkinsonism and\/or cognitive impairment with valproic acid therapy: a report of ten cases. Pharmacopsychiatry. 2006;39(1):9\u201312.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"937_CR131","first-page":"177","volume":"45","author":"MM Mehndiratta","year":"2005","unstructured":"Mehndiratta MM, Satyawani M, Gupta S, Khwaja GA. Clinical and surface EMG characteristics of valproate induced tremors. Electromyogr Clin Neurophysiol. 2005;45(3):177\u201382.","journal-title":"Electromyogr Clin Neurophysiol"},{"key":"937_CR132","doi-asserted-by":"publisher","first-page":"615","DOI":"10.5334\/tohm.424","volume":"8","author":"A Gupta","year":"2018","unstructured":"Gupta A, Kushwaha S. Disabling resting tremors induced by the short-term infusion of valproate: a reversible phenomenon. Tremor Other Hyperkinet Mov (N Y). 2018;8:615.","journal-title":"Tremor Other Hyperkinet Mov (N Y)."},{"issue":"2","key":"937_CR133","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/j.0013-9580.2005.36204.x","volume":"46","author":"M Rinnerthaler","year":"2005","unstructured":"Rinnerthaler M, Luef G, Mueller J, Seppi K, Wissel J, Trinka E, et al. Computerized tremor analysis of valproate-induced tremor: a comparative study of controlled-release versus conventional valproate. Epilepsia. 2005;46(2):320\u20133.","journal-title":"Epilepsia"},{"key":"937_CR134","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.parkreldis.2017.09.011","volume":"44","author":"M Alonso-Juarez","year":"2017","unstructured":"Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, Baizabal-Carvallo JF. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017;44:147\u201350.","journal-title":"Parkinsonism Relat Disord"},{"issue":"2","key":"937_CR135","first-page":"37","volume":"13","author":"P Nasr Esfahani","year":"2019","unstructured":"Nasr Esfahani P, Nasiri J, Badihian S, Yaghini O. Short-term side effects of low dose valproate monotherapy in epileptic children: a prospective study. Iran J Child Neurol. 2019;13(2):37\u201346.","journal-title":"Iran J Child Neurol."},{"issue":"10","key":"937_CR136","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1136\/jnnp.46.10.963","volume":"46","author":"V Chandra","year":"1983","unstructured":"Chandra V, Spunt AL, Rusinowitz MS. Treatment of post-traumatic choreo-athetosis with sodium valproate. J Neurol Neurosurg Psychiatry. 1983;46(10):963.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"937_CR137","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1532-5415.1990.tb01598.x","volume":"38","author":"AS Hoffman","year":"1990","unstructured":"Hoffman AS, Feinberg TE. Successful treatment of age-related chorea with sodium valproate. J Am Geriatr Soc. 1990;38(1):56\u20138.","journal-title":"J Am Geriatr Soc"},{"issue":"6283","key":"937_CR138","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/bmj.283.6283.17","volume":"283","author":"RJ Lenton","year":"1981","unstructured":"Lenton RJ, Copti M, Smith RG. Hemiballismus treated with sodium valproate. Br Med J (Clin Res Ed). 1981;283(6283):17\u20138.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6286","key":"937_CR139","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1136\/bmj.283.6286.274","volume":"283","author":"RS McLachlan","year":"1981","unstructured":"McLachlan RS. Valproic acid in Sydenham\u2019s chorea. Br Med J (Clin Res Ed). 1981;283(6286):274\u20135.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"937_CR140","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.35.1.114","volume":"35","author":"M Dhanaraj","year":"1985","unstructured":"Dhanaraj M, Radhakrishnan AR, Srinivas K, Sayeed ZA. Sodium valproate in Sydenham\u2019s chorea. Neurology. 1985;35(1):114\u20135.","journal-title":"Neurology"},{"issue":"3","key":"937_CR141","doi-asserted-by":"publisher","first-page":"140","DOI":"10.14712\/23362936.2021.14","volume":"122","author":"JP Rissardo","year":"2021","unstructured":"Rissardo JP, Caprara ALF, Durante I. Valproate-associated movement disorder: a literature review. Prague Med Rep. 2021;122(3):140\u201380.","journal-title":"Prague Med Rep"},{"issue":"4","key":"937_CR142","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/01.jcp.0000264989.63227.82","volume":"27","author":"B Habermeyer","year":"2007","unstructured":"Habermeyer B, Rabovsky K, Jentzsch C, Pinhard K, Muller-Spahn F. Cervical dystonia due to interaction of valproic acid and quetiapine. J Clin Psychopharmacol. 2007;27(4):396\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"937_CR143","first-page":"313","volume":"299","author":"S Fahn","year":"1978","unstructured":"Fahn S. Post-anoxic action myoclonus: improvement with valproic acid. N Engl J Med. 1978;299(6):313\u20134.","journal-title":"N Engl J Med"},{"issue":"1","key":"937_CR144","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s13311-013-0216-3","volume":"11","author":"JN Caviness","year":"2014","unstructured":"Caviness JN. Treatment of myoclonus. Neurotherapeutics. 2014;11(1):188\u2013200.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"937_CR145","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/WNF.0000000000000013","volume":"37","author":"L Ye","year":"2014","unstructured":"Ye L, Lippmann S. Tourette disorder treated with valproic acid. Clin Neuropharmacol. 2014;37(1):36\u20137.","journal-title":"Clin Neuropharmacol"},{"issue":"6345","key":"937_CR146","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1136\/bmj.285.6345.853","volume":"285","author":"MJ Brennan","year":"1982","unstructured":"Brennan MJ, Ruff P, Sandyk R. Efficacy of a combination of sodium valproate and baclofen in Meige\u2019s disease (idiopathic orofacial dystonia). Br Med J (Clin Res Ed). 1982;285(6345):853.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"6","key":"937_CR147","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1159\/000116704","volume":"31","author":"F Borggreve","year":"1991","unstructured":"Borggreve F, Hageman G. A case of idiopathic palatal myoclonus: treatment with sodium valproate. Eur Neurol. 1991;31(6):403\u20134.","journal-title":"Eur Neurol"},{"key":"937_CR148","doi-asserted-by":"crossref","unstructured":"Serrano-Duenas M. Use of primidone in low doses (250 mg\/day) versus high doses (750 mg\/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. Parkinsonism Relat Disord. 2003;10(1):29\u201333.","DOI":"10.1016\/S1353-8020(03)00070-1"},{"issue":"5","key":"937_CR149","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1136\/jnnp.55.5.413","volume":"55","author":"N Turjanski","year":"1992","unstructured":"Turjanski N, Lees AJ. Gamma vinyl GABA in the treatment of levodopa-induced dyskinesias in Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry. 1992;55(5):413.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"937_CR150","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0165-1781(83)90014-8","volume":"8","author":"S Korsgaard","year":"1983","unstructured":"Korsgaard S, Casey DE, Gerlach J. Effect of gamma-vinyl GABA in tardive dyskinesia. Psychiatry Res. 1983;8(4):261\u20139.","journal-title":"Psychiatry Res"},{"issue":"4","key":"937_CR151","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1002\/mds.870050413","volume":"5","author":"KD Sethi","year":"1990","unstructured":"Sethi KD, Hitri A, Diamond BI. Phenytoin potentiation of neuroleptic-induced dyskinesias. Mov Disord. 1990;5(4):325\u20137.","journal-title":"Mov Disord"},{"issue":"9","key":"937_CR152","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/WNL.57.9.1717","volume":"57","author":"S Happe","year":"2001","unstructured":"Happe S, Klosch G, Saletu B, Zeitlhofer J. Treatment of idiopathic restless legs syndrome (RLS) with gabapentin. Neurology. 2001;57(9):1717\u20139.","journal-title":"Neurology"},{"issue":"1","key":"937_CR153","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/mds.21188","volume":"22","author":"D Jamora","year":"2007","unstructured":"Jamora D, Lim SH, Pan A, Tan L, Tan EK. Valproate-induced Parkinsonism in epilepsy patients. Mov Disord. 2007;22(1):130\u20133.","journal-title":"Mov Disord"},{"issue":"12","key":"937_CR154","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1212\/WNL.31.12.1555","volume":"31","author":"WJ Weiner","year":"1981","unstructured":"Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasm-oromandibular dystonia) after long-term neuroleptic therapy. Neurology. 1981;31(12):1555\u20136.","journal-title":"Neurology"},{"issue":"2","key":"937_CR155","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.pnpbp.2004.11.022","volume":"29","author":"T Masui","year":"2005","unstructured":"Masui T, Kusumi I, Takahashi Y, Koyama T. Efficacy of carbamazepine against neuroleptic-induced akathisia in treatment with perospirone: case series. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):343\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"937_CR156","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S0887-8994(00)00177-6","volume":"23","author":"L Harel","year":"2000","unstructured":"Harel L, Zecharia A, Straussberg R, Volovitz B, Amir J. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol. 2000;23(2):147\u201351.","journal-title":"Pediatr Neurol"},{"issue":"6","key":"937_CR157","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/archneur.1982.00510180054014","volume":"39","author":"BP Garg","year":"1982","unstructured":"Garg BP. Dystonia musculorum deformans: implications of therapeutic response to levodopa and carbamazepine. Arch Neurol. 1982;39(6):376\u20137.","journal-title":"Arch Neurol"},{"issue":"2","key":"937_CR158","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3109\/02699059109008092","volume":"5","author":"RL Harmon","year":"1991","unstructured":"Harmon RL, Long DF, Shirtz J. Treatment of post-traumatic midbrain resting-kinetic tremor with combined levodopa\/carbidopa and carbamazepine. Brain Inj. 1991;5(2):213\u20138.","journal-title":"Brain Inj"},{"issue":"3","key":"937_CR159","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000114803","volume":"15","author":"C Loeb","year":"1977","unstructured":"Loeb C, Priano A. Preliminary evaluation of the effects of clonazepam on parkinsonian tremor. Eur Neurol. 1977;15(3):143\u20135.","journal-title":"Eur Neurol"},{"issue":"738","key":"937_CR160","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/pgmj.63.738.311-a","volume":"63","author":"MA Gillman","year":"1987","unstructured":"Gillman MA, Sandyk R. Clonazepam-induced Tourette syndrome in a subject with hyperexplexia. Postgrad Med J. 1987;63(738):311\u20132.","journal-title":"Postgrad Med J"},{"issue":"3","key":"937_CR161","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00004583-199403000-00014","volume":"33","author":"RJ Steingard","year":"1994","unstructured":"Steingard RJ, Goldberg M, Lee D, DeMaso DR. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry. 1994;33(3):394\u20139.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"3","key":"937_CR162","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1212\/WNL.37.3.471","volume":"37","author":"N Biary","year":"1987","unstructured":"Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987;37(3):471\u20134.","journal-title":"Neurology"},{"issue":"6","key":"937_CR163","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1002\/mds.870130622","volume":"13","author":"PC Jacob","year":"1998","unstructured":"Jacob PC, Pratap CR. Posttraumatic rubral tremor responsive to clonazepam. Mov Disord. 1998;13(6):977\u20138.","journal-title":"Mov Disord"},{"issue":"10","key":"937_CR164","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1212\/WNL.45.10.1951","volume":"45","author":"KR Edwards","year":"1995","unstructured":"Edwards KR. Felbamate and tremor. Neurology. 1995;45(10):1951.","journal-title":"Neurology"},{"issue":"6","key":"937_CR165","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1Q057","volume":"45","author":"S See","year":"2011","unstructured":"See S, Hendriks E, Hsiung L. Akathisia induced by gabapentin withdrawal. Ann Pharmacother. 2011;45(6): e31.","journal-title":"Ann Pharmacother"},{"issue":"2","key":"937_CR166","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/j.1532-849X.2012.00914.x","volume":"22","author":"AS Madani","year":"2013","unstructured":"Madani AS, Abdollahian E, Khiavi HA, Radvar M, Foroughipour M, Asadpour H, et al. The efficacy of gabapentin versus stabilization splint in management of sleep bruxism. J Prosthodont. 2013;22(2):126\u201331.","journal-title":"J Prosthodont"},{"issue":"3","key":"937_CR167","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10067-007-0744-5","volume":"27","author":"TA Zesiewicz","year":"2008","unstructured":"Zesiewicz TA, Shimberg WR, Hauser RA, Robinson W, Wilson MC, Sullivan KL. Chorea as a side effect of gabapentin (Neurontin) in a patient with complex regional pain syndrome type 1. Clin Rheumatol. 2008;27(3):389\u201390.","journal-title":"Clin Rheumatol"},{"issue":"4","key":"937_CR168","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1111\/j.1528-1157.2000.tb00192.x","volume":"41","author":"J Asconape","year":"2000","unstructured":"Asconape J, Diedrich A, DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia. 2000;41(4):479\u201381.","journal-title":"Epilepsia"},{"issue":"1","key":"937_CR169","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S0002-9343(96)00381-6","volume":"102","author":"WL Olson","year":"1997","unstructured":"Olson WL, Gruenthal M, Mueller ME, Olson WH. Gabapentin for parkinsonism: a double-blind, placebo-controlled, crossover trial. Am J Med. 1997;102(1):60\u20136.","journal-title":"Am J Med"},{"issue":"2","key":"937_CR170","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/15622970701332520","volume":"9","author":"YC Shen","year":"2008","unstructured":"Shen YC. Lamotrigine in motor and mood symptoms of Huntington\u2019s disease. World J Biol Psychiatry. 2008;9(2):147\u20139.","journal-title":"World J Biol Psychiatry"},{"key":"937_CR171","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.seizure.2016.02.009","volume":"37","author":"F Li","year":"2016","unstructured":"Li F, Lin ZD, Hu Y, Li W, Xue CC, Poonit ND. Lamotrigine monotherapy for paroxysmal kinesigenic dyskinesia in children. Seizure. 2016;37:41\u20134.","journal-title":"Seizure"},{"issue":"1","key":"937_CR172","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.sleep.2004.10.009","volume":"6","author":"EA Youssef","year":"2005","unstructured":"Youssef EA, Wagner ML, Martinez JO, Hening W. Pilot trial of lamotrigine in the restless legs syndrome. Sleep Med. 2005;6(1):89.","journal-title":"Sleep Med"},{"issue":"4","key":"937_CR173","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1176\/jnp.2007.19.4.474","volume":"19","author":"DN Mendhekar","year":"2007","unstructured":"Mendhekar DN, Duggal HS. Acquired variant of Rett\u2019s disorder and response to lamotrigine. J Neuropsychiatry Clin Neurosci. 2007;19(4):474\u20135.","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"937_CR174","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/JCP.0b013e31823fa929","volume":"32","author":"A Ortiz","year":"2012","unstructured":"Ortiz A, Alda M, O\u2019Donovan C. Tourette syndrome with comorbid bipolar disorder and migraine: can lamotrigine monotherapy help? J Clin Psychopharmacol. 2012;32(1):140\u20132.","journal-title":"J Clin Psychopharmacol"},{"issue":"11","key":"937_CR175","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1002\/mds.21061","volume":"21","author":"TA Zesiewicz","year":"2006","unstructured":"Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington\u2019s disease. Mov Disord. 2006;21(11):1998\u20132001.","journal-title":"Mov Disord"},{"issue":"4","key":"937_CR176","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1097\/wnf.0b013e31803b9415","volume":"30","author":"M Alemdar","year":"2007","unstructured":"Alemdar M, Iseri P, Selekler M, Komsuoglu SS. Levetiracetam-responding paroxysmal nonkinesigenic dyskinesia. Clin Neuropharmacol. 2007;30(4):241\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"12","key":"937_CR177","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/mds.20233","volume":"19","author":"TA Zesiewicz","year":"2004","unstructured":"Zesiewicz TA, Louis ED, Sullivan KL, Menkin M, Dunne PB, Hauser RA. Substantial improvement in a Meige\u2019s syndrome patient with levetiracetam treatment. Mov Disord. 2004;19(12):1518\u201321.","journal-title":"Mov Disord"},{"issue":"4","key":"937_CR178","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1097\/01.wnf.0000169732.00690.32","volume":"28","author":"TA Zesiewicz","year":"2005","unstructured":"Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol. 2005;28(4):188\u201390.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"937_CR179","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.braindev.2010.09.008","volume":"33","author":"A Gagliano","year":"2011","unstructured":"Gagliano A, Arico I, Calarese T, Condurso R, Germano E, Cedro C, et al. Restless leg syndrome in ADHD children: levetiracetam as a reasonable therapeutic option. Brain Dev. 2011;33(6):480\u20136.","journal-title":"Brain Dev"},{"issue":"6","key":"937_CR180","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ejpn.2008.12.006","volume":"13","author":"A Fernandez-Jaen","year":"2009","unstructured":"Fernandez-Jaen A, Fernandez-Mayoralas DM, Munoz-Jareno N, Calleja-Perez B. An open-label, prospective study of levetiracetam in children and adolescents with Tourette syndrome. Eur J Paediatr Neurol. 2009;13(6):541\u20135.","journal-title":"Eur J Paediatr Neurol"},{"issue":"3","key":"937_CR181","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1177\/1352458508099142","volume":"15","author":"P Feys","year":"2009","unstructured":"Feys P, D\u2019Hooghe MB, Nagels G, Helsen WF. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler. 2009;15(3):371\u20138.","journal-title":"Mult Scler"},{"issue":"10","key":"937_CR182","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.parkreldis.2009.03.007","volume":"15","author":"EE Okuyucu","year":"2009","unstructured":"Okuyucu EE, Duman T, Akcin E. Reversible parkinsonism with oxcarbazepine use. Parkinsonism Relat Disord. 2009;15(10):787\u20138.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"937_CR183","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/000992289203100413","volume":"31","author":"A Lacayo","year":"1992","unstructured":"Lacayo A, Mitra N. Report of a case of phenobarbital-induced dystonia. Clin Pediatr (Phila). 1992;31(4):252.","journal-title":"Clin Pediatr (Phila)"},{"issue":"1","key":"937_CR184","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/0887-8994(86)90042-1","volume":"2","author":"R Sandyk","year":"1986","unstructured":"Sandyk R. Phenobarbital-induced Tourette-like symptoms. Pediatr Neurol. 1986;2(1):54\u20135.","journal-title":"Pediatr Neurol"},{"issue":"1","key":"937_CR185","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.parkreldis.2008.01.015","volume":"15","author":"A Bonakis","year":"2009","unstructured":"Bonakis A, Papageorgiou SG, Potagas C, Karahalios G, Kalfakis N. A case of refractory secondary paroxysmal kinesigenic dyskinesia with high sensitivity to phenytoin monotherapy. Parkinsonism Relat Disord. 2009;15(1):68\u201370.","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"937_CR186","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1345\/aph.1R699","volume":"47","author":"E Dag","year":"2013","unstructured":"Dag E, Gokce B, Buturak SV, Tiryaki D, Erdemoglu AK. Pregabalin-induced akathisia. Ann Pharmacother. 2013;47(4):592\u20133.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"937_CR187","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/WNF.0b013e31825bd3d7","volume":"35","author":"WS Baek","year":"2012","unstructured":"Baek WS. Pregabalin resolves refractory aparathyroid paroxysmal kinesigenic choreoathetosis. Clin Neuropharmacol. 2012;35(4):203.","journal-title":"Clin Neuropharmacol"},{"issue":"6","key":"937_CR188","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1046\/j.1528-1157.2001.44000.x","volume":"42","author":"HJ Huppertz","year":"2001","unstructured":"Huppertz HJ, Feuerstein TJ, Schulze-Bonhage A. Myoclonus in epilepsy patients with anticonvulsive add-on therapy with pregabalin. Epilepsia. 2001;42(6):790\u20132.","journal-title":"Epilepsia"},{"issue":"6","key":"937_CR189","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1097\/WNF.0b013e3181a9eb1b","volume":"32","author":"S Perez Lloret","year":"2009","unstructured":"Perez Lloret S, Amaya M, Merello M. Pregabalin-induced parkinsonism: a case report. Clin Neuropharmacol. 2009;32(6):353\u20134.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"937_CR190","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/mds.22961","volume":"25","author":"L Coltamai","year":"2010","unstructured":"Coltamai L, Magezi DA, Croquelois A. Pregabalin in the treatment of neuropathic tremor following a motor axonal form of Guillain-Barre syndrome. Mov Disord. 2010;25(4):517\u20139.","journal-title":"Mov Disord"},{"issue":"8","key":"937_CR191","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1212\/WNL.38.8.1332","volume":"38","author":"A van der Zwan","year":"1988","unstructured":"van der Zwan A, Verwey JC, van Gijn J. Relief of orthostatic tremor by primidone. Neurology. 1988;38(8):1332.","journal-title":"Neurology"},{"issue":"3","key":"937_CR192","doi-asserted-by":"publisher","first-page":"102","DOI":"10.2344\/0003-3006(2005)52[102:TMRBAA]2.0.CO;2","volume":"52","author":"RE Kast","year":"2005","unstructured":"Kast RE. Tiagabine may reduce bruxism and associated temporomandibular joint pain. Anesth Prog. 2005;52(3):102\u20134.","journal-title":"Anesth Prog"},{"issue":"3","key":"937_CR193","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1097\/JCP.0b013e3181dbfc0b","volume":"30","author":"A Mowla","year":"2010","unstructured":"Mowla A, Sabayan B. Topiramate for bruxism: report of 2 cases. J Clin Psychopharmacol. 2010;30(3):346\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"937_CR194","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s00415-005-0029-3","volume":"253","author":"S Papapetropoulos","year":"2006","unstructured":"Papapetropoulos S, Singer C. Improvement of cervico-trunco-brachial segmental dystonia with topiramate. J Neurol. 2006;253(4):535\u20136.","journal-title":"J Neurol"},{"issue":"14","key":"937_CR195","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.2146\/ajhp090185","volume":"67","author":"AD Miller","year":"2010","unstructured":"Miller AD, Prost VM, Bookstaver PB, Gaines KJ. Topiramate-induced myoclonus and psychosis during migraine prophylaxis. Am J Health Syst Pharm. 2010;67(14):1178\u201380.","journal-title":"Am J Health Syst Pharm"},{"issue":"11","key":"937_CR196","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/mds.20217","volume":"19","author":"A Siniscalchi","year":"2004","unstructured":"Siniscalchi A, Mancuso F, Russo E, Ibbadu GF, De Sarro G. Spinal myoclonus responsive to topiramate. Mov Disord. 2004;19(11):1380\u20131.","journal-title":"Mov Disord"},{"issue":"4","key":"937_CR197","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1007\/s00415-009-0073-5","volume":"256","author":"PE Bermejo","year":"2009","unstructured":"Bermejo PE. Restless legs syndrome induced by topiramate: two more cases. J Neurol. 2009;256(4):662\u20133.","journal-title":"J Neurol"},{"issue":"10","key":"937_CR198","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1002\/mds.23119","volume":"25","author":"S Srinivasan","year":"2010","unstructured":"Srinivasan S, Lok AW. Valproate-induced reversible hemichorea. Mov Disord. 2010;25(10):1511\u20132.","journal-title":"Mov Disord"},{"key":"937_CR199","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1192\/bjp.129.2.114","volume":"129","author":"M Linnoila","year":"1976","unstructured":"Linnoila M, Viukari M, Kietala O. Effect of sodium valproate on tardive dyskinesia. Br J Psychiatry. 1976;129:114\u20139.","journal-title":"Br J Psychiatry"},{"key":"937_CR200","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12991-019-0245-3","volume":"18","author":"D Tao","year":"2019","unstructured":"Tao D, Zhong T, Ma S, Li J, Li X. Randomized controlled clinical trial comparing the efficacy and tolerability of aripiprazole and sodium valproate in the treatment of Tourette syndrome. Ann Gen Psychiatry. 2019;18:24.","journal-title":"Ann Gen Psychiatry"},{"issue":"16","key":"937_CR201","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1212\/01.wnl.0000259537.54082.6d","volume":"68","author":"V Leuzzi","year":"2007","unstructured":"Leuzzi V, Di Sabato ML, Deodato F, Rizzo C, Boenzi S, Carducci C, et al. Vigabatrin improves paroxysmal dystonia in succinic semialdehyde dehydrogenase deficiency. Neurology. 2007;68(16):1320\u20131.","journal-title":"Neurology"},{"issue":"1\u20132","key":"937_CR202","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jns.2011.12.010","volume":"315","author":"Y Iwata","year":"2012","unstructured":"Iwata Y, Irie S, Uchida H, Suzuki T, Watanabe K, Iwashita S, et al. Effects of zonisamide on tardive dyskinesia: a preliminary open-label trial. J Neurol Sci. 2012;315(1\u20132):137\u201340.","journal-title":"J Neurol Sci"},{"issue":"10","key":"937_CR203","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/mds.21449","volume":"22","author":"PEB Velasco","year":"2007","unstructured":"Velasco PEB, Goiburu JAZ, Pinel RS. Restless legs syndrome induced by zonisamide. Mov Disord. 2007;22(10):1517\u20138.","journal-title":"Mov Disord"},{"issue":"3","key":"937_CR204","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1002\/mds.22418","volume":"24","author":"A Handforth","year":"2009","unstructured":"Handforth A, Martin FC, Kang GA, Vanek Z. Zonisamide for essential tremor: an evaluator-blinded study. Mov Disord. 2009;24(3):437\u201340.","journal-title":"Mov Disord"},{"issue":"1","key":"937_CR205","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00415-011-6127-5","volume":"259","author":"S Suda","year":"2012","unstructured":"Suda S, Yamazaki M, Katsura K, Fukuchi T, Kaneko N, Ueda M, et al. Dramatic response to zonisamide of post-subarachnoid hemorrhage Holmes\u2019 tremor. J Neurol. 2012;259(1):185\u20137.","journal-title":"J Neurol"}],"updated-by":[{"DOI":"10.1007\/s40263-022-00947-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T00:00:00Z","timestamp":1660694400000}}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-022-00937-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-022-00937-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T16:10:49Z","timestamp":1660752649000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-022-00937-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,21]]},"references-count":205,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["937"],"URL":"https:\/\/doi.org\/10.1007\/s40263-022-00937-x","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40263-022-00947-9","asserted-by":"object"}]},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,21]]},"assertion":[{"value":"30 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40263-022-00947-9","URL":"https:\/\/doi.org\/10.1007\/s40263-022-00947-9","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dawn Eliashiv serves on an advisory\/speaker bureau of Greenwich, Eisai, Sunovion, UCB, and Livanova. Michel S\u00e1enz-Farret, Marina Tijssen, Robert S. Fisher, Kapil Sethi, and Alfonso Fasano have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"1. Research project: A. Conception, B. Organization, C. Execution; 2. Statistical analysis: A. Design, B. Execution, C. Review and critique; 3. Manuscript preparation: A. Writing of the first draft, B. Review and critique. MS-F: 1B, 1C, 3A; MAJT: 3C; DE: 3C; RSF: 3C; KS: 3C; AF: 1A, 1B, 3C. AF had the idea for this article. MS-F and AF performed the literature search and data analysis. MAJT, DE, RSF, KS, and AF critically revised the work. All the authors have read and approve the final submitted manuscript, and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}